Press release
Postherpetic Neuralgia Market Size in 7MM is expected to witness a major change in the study period 2019-2032, estimates DelveInsight
"The Postherpetic Neuralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Postherpetic Neuralgia pipeline products will significantly revolutionize the Postherpetic Neuralgia market dynamics"The Postherpetic Neuralgia market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Postherpetic Neuralgia market size from 2019 to 2032. The report also covers current Postherpetic Neuralgia treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Key Takeaways from the Postherpetic Neuralgia Market Report
• The increase in market size is a direct consequence of an increasing number of Postherpetic neuralgia patients in the 7MM and an improvement in the understanding of postherpetic neuraglia in the recent decades, leading to growing awareness, improved management, better outcomes, and increase in R&D activity for developing new molecules.
• According to DelveInsight's analysis, Postherpetic Neuralgia is more prominent in females in comparison to males.
• The leading Postherpetic Neuralgia Companies working in the market include Daiichi Sankyo Co., SRL Medisearch Inc., Quintiles Inc., KAI Pharmaceuticals, Trident Clinical Research Pty Ltd, Grünenthal GmbH, Pfizer, Winston Laboratories, Xenon Pharmaceuticals Inc., Bausch Health Americas Inc., ZARS Pharma Inc., Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Teva Pharamceuticals, Zalicus, and others.
• Promising Postherpetic Neuralgia Pipeline Therapies in the various stages of development include DS-5565, KAI-1678, Lidocaine, TRK-700, Pregabalin, Civamide Patch, XPF-002, Retigabine, SR419, HSK16149 20mg BID, LX9211, and others
• On March 2023, Shanghai SIMR Biotechnology Co., Ltd. announced a study of phase 2 clinical trials for SR419. This is a Phase II, international multicenter, double-blind, placebo-controlled, crossover study to assess the efficacy of SR419 in PHN subjects.
• On March 2023, Lexicon Pharmaceuticals announced a study of phase 2 clinical trials for LX9211. Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.
• On May 2023, UCB Pharma announced a study of phase 2 clinical trials for SPM927/Lacosamide. The objective of the trial is to investigate the analgesic efficacy of SPM 927 in subjects with moderate to severe neuropathic pain due to Postherpetic Neuralgia (PHN).
Discover more about therapies set to grab major Postherpetic Neuralgia Market Share @ Postherpetic Neuralgia Market Size- https://www.delveinsight.com/report-store/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Postherpetic Neuralgia Overview
Postherpetic neuralgia is a type of neuropathic pain that persists for more than three months after the resolution of the acute phase of herpes zoster infection. It is characterized by intense, burning, stabbing, or shooting pain in the affected dermatome (area of the skin supplied by a single nerve).
Postherpetic Neuralgia Epidemiology Segmentation in the 7MM
• Total Postherpetic neuralgia Incident Cases
• Postherpetic neuralgia Gender-Specific Cases
• Postherpetic neuralgia Site-Specific Cases
• Postherpetic neuralgia Age-Specific Cases
• Postherpetic neuralgia Treated Cases
Download the report to understand which factors are driving Postherpetic neuralgia Epidemiology Trends @ Postherpetic neuralgia Epidemiological Insights- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Postherpetic Neuralgia Market Insights
The duration of pain in postherpetic neuralgia can be highly variable, suggesting that multiple pathophysiological mechanisms may be involved. In addition, approximately 40% to 50% of patients with postherpetic neuralgia do not respond to any treatment, and other patients experience limited efficacy due to the inherent properties of the therapies. Treatment of Postherpetic neuralgia is often accompanied by intolerable side effects. SHRINGIX (GSK1437173A), a recombinant zoster vaccine, was approved for the prevention of herpes zoster (shingles). But as with any other vaccine, it is recommended for preventive use instead for the treatment of an acute event of herpes zoster like Postherpetic neuralgia.
Postherpetic Neuralgia Market Dynamics
The postherpetic neuralgia market dynamics is anticipated to change in the coming years due to the positive outcomes of the pipeline candidates during the developmental stage by key players, such as Lexicon Pharmaceuticals (LX9211), Confo Therapeutics (CFTX-1554) etc. All these therapies can create a positive shift in postherpetic neuralgia market size during the forecast period (2023-2032).
To know more about Postherpetic Neuralgia Treatment options, visit @ Postherpetic Neuralgia Drugs- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Postherpetic Neuralgia Market Outlook
The Postherpetic Neuralgia market outlook reflects a dynamic landscape marked by evolving therapeutic approaches and a growing emphasis on patient-centric care. PHN, a debilitating condition arising from the reactivation of the varicella-zoster virus, continues to pose significant challenges to both patients and healthcare providers. However, advancements in medical research and innovative treatments have offered renewed hope.
Postherpetic Neuralgia Treatment Market
The Postherpetic Neuralgia Treatment Market refers to the industry segment dedicated to addressing the complex and often debilitating condition known as Postherpetic neuralgia (PHN). PHN is a chronic pain syndrome that can develop following an outbreak of herpes zoster, commonly known as shingles.
Learn more about the Postherpetic Neuralgia Pipeline Therapies in clinical trials @ Postherpetic Neuralgia Market Landscape- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Postherpetic Neuralgia Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Postherpetic Neuralgia Companies- Daiichi Sankyo Co., SRL Medisearch Inc., Quintiles Inc., KAI Pharmaceuticals, Trident Clinical Research Pty Ltd, Grünenthal GmbH, Pfizer, Winston Laboratories, Xenon Pharmaceuticals Inc., Bausch Health Americas Inc., ZARS Pharma Inc., Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Teva Pharamceuticals, Zalicus, and others.
• Postherpetic Neuralgia Pipeline Therapies- DS-5565, KAI-1678, Lidocaine, TRK-700, Pregabalin, Civamide Patch, XPF-002, Retigabine, SR419, HSK16149 20mg BID, LX9211, and others.
• Postherpetic Neuralgia Market Dynamics: Postherpetic Neuralgia Market Drivers and Barriers
• Postherpetic Neuralgia Market Access and Reimbursement, Analyst Views, Unmet Needs
Discover more about Postherpetic Neuralgia Drugs in development @ Postherpetic Neuralgia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Postherpetic Neuralgia
3. Competitive Intelligence Analysis for Postherpetic Neuralgia
4. Postherpetic Neuralgia: Market Overview at a Glance
5. Postherpetic Neuralgia: Disease Background and Overview
6. Patient Journey
7. Postherpetic Neuralgia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Postherpetic Neuralgia Unmet Needs
10. Key Endpoints of Postherpetic Neuralgia Treatment
11. Postherpetic Neuralgia Marketed Products
12. Postherpetic Neuralgia Emerging Therapies
13. Postherpetic Neuralgia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Postherpetic Neuralgia
17. KOL Views
18. Postherpetic Neuralgia Market Drivers
19. Postherpetic Neuralgia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Get in touch with our Business executive @ Postherpetic Neuralgia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links-
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/
https://onlyfans.com/dennydones9
https://maker.wiznet.io/dennydones9
https://collab.sundance.org/people/Denny-Dones-1699939772
https://insurtechasia.mn.co/posts/45403575
https://meganto-lottery.mn.co/posts/45403650
https://ylimun.mn.co/posts/45403740
https://network-79379.mn.co/posts/45404061
https://acatpg.mn.co/posts/45404422
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Postherpetic Neuralgia Market Size in 7MM is expected to witness a major change in the study period 2019-2032, estimates DelveInsight here
News-ID: 3290436 • Views: …
More Releases from DelveInsight

Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunothe …
DelveInsight's "Lung Adenocarcinoma - Clinical Trials Analysis, 2025" describes a dynamic and fast-moving development landscape focusing on two complementary goals: (1) inhibit tumor growth and progression through targeted and immune-based therapies, and (2) improve patient survival, quality of life, and functional outcomes. Current programs include EGFR, ALK, KRAS, and MET inhibitors, immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), and emerging bispecific antibodies and combination regimens designed to overcome resistance and enhance efficacy.
Late-stage…

Neurofibromatosis Type 1 Clinical Trials Analysis 2025: Targeted RAS-Pathway and …
The Neurofibromatosis Type 1 (NF1) clinical trial landscape in 2025 focuses on two main goals: controlling plexiform and cutaneous neurofibromas and preventing malignant peripheral nerve sheath tumors (MPNST) while improving quality of life. Current programs include RAS-MAPK pathway inhibitors, next-generation MEK inhibitors, mTOR modulators, immuno-oncology agents for MPNST, and early gene-directed therapies.
Late-stage trials primarily test oral RAS pathway inhibitors for pediatric plexiform neurofibromas, with attention to safety, functional improvement, and…

Neisseria Meningitidis Meningitis Clinical Trials Analysis 2025: Multivalent Vac …
DelveInsight's "Neisseria Meningitidis Meningitis - Clinical Trials Analysis, 2025" outlines a rapidly evolving landscape aimed at two primary goals: (1) provide broad serogroup coverage through next-generation multivalent and protein-based vaccines, and (2) improve long-term immunity and reduce disease incidence in adolescents, young adults, and high-risk populations. Ongoing programs include conjugate vaccines, adjuvanted formulations, and combination vaccines targeting meningococcal and other pediatric pathogens to optimize immunization schedules.
Late-stage and pivotal trials focus…

Essential Tremor Clinical Trials Analysis 2025: Novel Pharmacologics, Neuromodul …
DelveInsight's "Essential Tremor - Clinical Trials Analysis, 2025" highlights a dynamic development landscape focused on two complementary goals: (1) reduce tremor severity and improve motor control, and (2) enhance patient quality of life and daily functioning. Ongoing programs include small-molecule pharmacologics targeting GABAergic and calcium channel pathways, focused ultrasound neuromodulation, deep brain stimulation (DBS) refinements, and emerging gene therapy candidates aimed at long-term tremor suppression.
Late-stage and registration-enabling trials assess efficacy,…
More Releases for Postherpetic
Postherpetic Neuralgia Market Trends, Treatments, and Growth Opportunities
Postherpetic neuralgia (PHN) is a debilitating complication of shingles (herpes zoster), causing chronic nerve pain that significantly affects patients' quality of life. The Postherpetic Neuralgia Market has gained substantial attention in recent years, as healthcare providers, pharmaceutical companies, and research organizations work toward effective pain management solutions. The growing prevalence of shingles, aging populations, and advances in therapeutic interventions underscore the critical need for innovative PHN treatments.
Download Full PDF Sample…
Postherpetic Neuralgia (PHN) Market: Major Trends Reshaping the Future of the In …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Postherpetic Neuralgia (PHN) Industry Market Size Be by 2025?
The market for postherpetic neuralgia (phn) has witnessed significant growth lately. The market, which was worth $0.72 billion in 2024, is projected to increase to $0.77 billion by 2025, showcasing a compound annual growth rate (CAGR) of…
Postherpetic Neuralgia Market Is Going to Boom | Major Giants Pfizer, Teva, Glax …
HTF MI just released the Global Postherpetic Neuralgia Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in Postherpetic Neuralgia Market are: Pfizer, Teva, GlaxoSmithKline,…
Postherpetic Neuralgia Pipeline, Therapeutics Assessment, Clinical Trials, Drugs …
DelveInsight's, "Postherpetic Neuralgia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in…
Postherpetic Neuralgia Treatment Drugs, Pipeline Insights Report 2024
DelveInsight's, "Postherpetic Neuralgia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in…
Postherpetic Neuralgia Market Forecast: Navigating Growth, Trends, and Key Playe …
"Posrpetic Neuralgia Market Was Valued At US$ 803 Million In 2024 And Is Projected To Grow At A Cagr Of 5.6% To Reach US$ 1320.9 Million By 2034.".
With thorough company profiles, recent developments, and other information, the Postherpetic Neuralgia Market Report provides an in-depth analysis of major trends, motivating reasons, obstacles, segmentation, regulatory policies, and important players. The Postherpetic Neuralgia Market Report offers a thorough synopsis of the product portfolio,…